- $196.39m
- $200.62m
- $52.84m
Apyx Medical Corp reports results for the quarter ended in June - Earnings Summary
Brief: Apyx Medical Corp Reports Second Quarter 2022 Financial Results
Apyx Medical Corp expected to post a loss of 19 cents a share - Earnings Preview
Apyx Medical rises on FDA clearance for loose skin treatment device
Brief: Apyx Medical Receives FDA 510(K) Clearance For Use Of Renuvion
Brief: Apyx Medical Announces Results Of U.S. Ide Clinical Study Evaluating The Use Of Renuvion To Improve Appearance Of Lax Skin
Brief: Apyx Medical Corp Says Renuvion Dermal Handpiece For Wrinkle-Reduction Procedures Cleared By FDA
Brief: Apyx Medical Corp Says On June 6, Complaint Was Filed In United States District Court For Middle District Of Florida By Plaintiff William E. Hattaway
Brief: FDA Updates Recommendations For Use Of Renuvion/J-Plasma Device For Certain Aesthetic Procedures
Brief: Apyx Medical Receives FDA 510(K) Clearance For Renuvion Cosmetic Technology In Dermal Resurfacing Procedures
U.S. RESEARCH ROUNDUP-First Solar, Henry Schein, Petiq
Apyx Medical Corp reports results for the quarter ended in March - Earnings Summary
Brief: Apyx Medical Corporation Reports First Quarter 2022 Financial Results And Updates Full Year 2022 Financial Outlook
Apyx Medical Corp expected to post a loss of 15 cents a share - Earnings Preview
Brief: Apyx Medical Corp Announces FDA 510(K) Submission With Clinical Study Support For Use Of Renuvion APR Handpiece For Aesthetic Procedures To Improve Appearance Of Lax Skin
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Joann, Park Ohio Holdings
Apyx Medical Corp reports results for the quarter ended in December - Earnings Summary
Brief: Apyx Medical Reports Q4, Full Year 2021 Financial Results
Apyx Medical Corp expected to post a loss of 11 cents a share - Earnings Preview